Abstract:Mai Zhang, 1 Yan Li, 1, 2 Chunli Han, 3 Shiying Chu, 1 Peng Yu, 1 Wenbo Cheng 1, 2 1 Mass Spectrometry Application Center, Tianjin Guoke Medical Technology Development Co., Ltd, Tianjin, People's Republic of China; 2 Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences (CAS), Suzhou, People's Republic of China; 3 Mass Spectrometry Application Center, Shandong CAS Intelligent Manufacturing Medical Device Technology Co., Ltd, Zaozhuang, People's Republic of China Correspondence: Wenbo Cheng, Email Background: Inhibition of amyloid β protein fragment (Aβ) aggregation is considered to be one of the most effective strategies for the treatment of Alzheimer's disease. (-)-Epigallocatechin-3-gallate (EGCG) has been found to be effective in this regard; however, owing to its low bioavailability, nanodelivery is recommended for practical applications. Compared to chemical reduction methods, biosynthesis avoids possible biotoxicity and cumbersome preparation processes. Materials and Methods: The interaction between EGCG and Aβ 42 was simulated by molecular docking, and green tea-conjugated gold nanoparticles (GT-Au NPs) and EGCG-Au NPs were synthesized using EGCG-enriched green tea and EGCG solutions, respectively. Surface active molecules of the particles were identified and analyzed using various liquid chromatography-tandem triple quadrupole mass spectrometry methods. ThT fluorescence assay, circular dichroism, and TEM were used to investigate the effect of synthesized particles on the inhibition of Aβ 42 aggregation. Results: EGCG as well as apigenin, quercetin, baicalin, and glutathione were identified as capping ligands stabilized on the surface of GT-Au NPs. They more or less inhibited Aβ 42 aggregation or promoted fibril disaggregation, with EGCG being the most effective, which bound to Aβ 42 through hydrogen bonding, hydrophobic interactions, etc. resulting in 39.86% and 88.50% inhibition of aggregation and disaggregation effects, respectively. EGCG-Au NPs were not as effective as free EGCG, whereas multiple thiols and polyphenols in green tea accelerated and optimized heavy metal detoxification. The synthesized GT-Au NPs conferred the efficacy of diverse ligands to the particles, with inhibition of aggregation and disaggregation effects of 54.69% and 88.75%, respectively, while increasing the yield, enhancing water solubility, and decreasing cost. Conclusion: Biosynthesis of nanoparticles using green tea is a promising simple and economical drug-carrying approach to confer multiple pharmacophore molecules to Au NPs. This could be used to design new drug candidates to treat Alzheimer's disease. Keywords: gold nanoparticles, green synthesis, (-)-epigallocatechin-3-gallate, liquid chromatography tandem triple quadrupole mass spectrometry, amyloid β protein, green tea Alzheimer's disease (AD) is a neurodegenerative disease with insidious onset and progressive progression. The Alzheimer's Disease International (ADI) 2018 Global Report stated that every three seconds, someone in the world will develop dementia. 1 Currently, the pathogenesis of AD is highly controversial, but the main pathological hallmark is the misfolding of extracellular amyloid β-protein (Aβ) and neurofibrillary tangles induced by intracellular tau proteins. 2,3 Consequently, inhibition of Aβ aggregation is considered to be one of the most effective strategies for the treatment of AD. A variety of chemicals, including peptides, 4 curcumin, 5 alginate, 6 resveratrol, 7 and quercetin, 8 have been shown to inhibit Aβ fibrillation. Therein, (-)-epigallocatechin-3-gallate (EGCG), one of the most effective substances for inhibiting Aβ aggregation and promoting mature fiber disaggregation, 9–12 was achieved through the interaction of its own phenolic ring with the aromatic residues of Aβ by hydrogen bonding, aromatic stacking, and hydrophobicity. 13,14 Furthermore, in addition to chelating metal ions and scavenging free radicals, 15–17 Seidler et al revealed that EGCG could disaggregate brain-derived tau fibrils in vitro, fully validating the wide array of therapeutic potential of EGCG. 18 However, the applicability of EGCG in humans has encountered with rather limited success largely due to its low stability, poor blood–brain barrier (BBB) permeability, and rapid metabolic clearance, 19 ultimately resulting in an absolute bioavailability of only 0.1%. 20 Accordingly, diversified forms of EGCG delivery systems have been designed in the clinical setup. 21–25 Istenič et al utilized liposomes to -Abstract Truncated-

Structural Remodeling Mechanism of the Toxic Amyloid Fibrillary Mediated by Epigallocatechin-3-gallate

Understanding the mechanisms of green tea EGCG against amyloid β oligomer neurotoxicity through computational studies

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting Aβ42 Protofibril.

Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro

Biosynthesis of Nanoparticles with Green Tea for Inhibition of β-Amyloid Fibrillation Coupled with Ligands Analysis

Green tea extract EGCG plays a dual role in Aβ42 protofibril disruption and membrane protection: A molecular dynamic study.

Inhibition Mechanisms of (-)-epigallocatechin-3-gallate and Genistein on Amyloid-beta 42 Peptide of Alzheimer's Disease Via Molecular Simulations

Natural compounds may open new routes to treatment of amyloid diseases

Molecular Insights into the Inhibition and Disaggregation Effects of EGCG on Aβ40 and Aβ42 Cofibrillation

Insights into Molecular Mechanisms of EGCG and Apigenin on Disrupting Amyloid-Beta Protofibrils Based on Molecular Dynamics Simulations

Inhibition of Aβ Aggregates in Alzheimer’s Disease by Epigallocatechin and Epicatechin-3-gallate from Green Tea

Molecular insight into conformational transition of amyloid β-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations.

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Molecular Mechanism of Cyanidin-3-O-Glucoside Disassembling Aβ Fibril in Silico

Epigallocatechin Gallate Destabilizes Α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface.

Synergistic Effects of Negatively Charged Hydrophobic Nanoparticles and (−)-Epigallocatechin-3-gallate on Inhibiting Amyloid Β-Protein Aggregation

The Inhibition Effect of Epigallocatechin-3-Gallate on the Co-Aggregation of Amyloid-β and Human Islet Amyloid Polypeptide Revealed by Replica Exchange Molecular Dynamics Simulations

Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer’s disease: an overview of pre-clinical studies focused on β-amyloid peptide

Epigallocatechin-3-gallate (Egcg)-Stabilized Selenium Nanoparticles Coated with Tet-1 Peptide to Reduce Amyloid-β Aggregation and Cytotoxicity

Recent Studies On Mechanisms Of New Drug Candidates For Alzheimer'S Disease Interacting With Amyloid-Beta Protofibrils Using Molecular Dynamics Simulations